Analyzing genetic mutations in cancer patients' blood and saliva
An Investigation of the Role of Germ-Line Mutations in Cancer Predisposition, Tumor Biology, and Response to Treatment
This study is testing whether looking at genetic changes in blood and saliva from cancer patients can help us understand their cancer risk and how well they respond to treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Jonsson Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT02280161 on ClinicalTrials.gov |
What this trial studies
This research focuses on collecting and analyzing germ-line DNA and nucleic acids from blood and saliva samples of cancer patients. The primary aim is to identify new germ-line mutations that may influence cancer predisposition and treatment responses. Additionally, the study investigates how these mutations correlate with cancer outcomes and the expression of related biological markers. Patients will provide samples 1-3 times, and they will be followed for five years to assess the long-term implications of these genetic factors.
Who should consider this trial
Good fit: Ideal candidates include individuals with a confirmed diagnosis of cancer who are willing to provide blood and saliva samples.
Not a fit: Patients whose cancer cannot be confirmed or who refuse to sign informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of genetic factors in cancer, leading to improved risk assessment and personalized treatment strategies.
How similar studies have performed: Other studies have shown promise in identifying genetic mutations related to cancer predisposition, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologically or clinical confirmed tissue diagnosis of a cancer * Ability to understand and the willingness to sign a written informed consent Exclusion Criteria: * Patients will be excluded if their cancer cannot be confirmed * Refusal to sign the informed consent
Where this trial is running
Los Angeles, California
- Jonsson Comprehensive Cancer Center — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Joanne Weidhaas — Jonsson Comprehensive Cancer Center
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.